Last reviewed · How we verify

NCT02673710

A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With Chemotherapy Combined With Bevacizumab

Completed Last updated 25 March 2020
What this trial tests

trial testing No intervention in Metastatic Colorectal Cancer in 200 participants. Completed in 4 February 2020.

Timeline
14 March 2016
Primary endpoint
4 February 2020
4 February 2020

Quick facts

Lead sponsorHoffmann-La Roche
StatusCompleted
Study typeOBSERVATIONAL
Enrollment200
Start date14 March 2016
Primary completion4 February 2020
Estimated completion4 February 2020
Sites23 locations across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

Hoffmann-La Roche — full company profile →

Who can join

18 and older, any sex, with Metastatic Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to explore the relationship between sarcopenia, as defined by computed tomography, treatment related outcomes and other body composition related parameters in a patient population receiving bevacizumab beyond progression.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Metastatic Colorectal Cancer

Currently open trials in the same condition.

Other Hoffmann-La Roche trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02673710.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing